Leading International Investment Research

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Leading International Investment Research, Edison Investment Research

Equity Bottom-Up

Abzena has announced the progression of one of the Abzena inside Composite Human Antibody products into a Phase II clinical trial. The product is being developed by a major US pharmaceutical company for the treatment of neurodegenerative conditions. We have increased our valuation to &#163;105m (vs &#163;102m) as a result of an increase of the Abzena inside product&#8217;s assigned probability (to 35% from 15%).

Abzena has announced the progression of one of the Abzena inside Composite Human Antibody products into a Phase II clinical trial. The product is being developed by a major US pharmaceutical company for the treatment of neurodegenerative conditions. We have increased our valuation to &#163;105m (vs &#163;102m) as a result of an increase of the Abzena inside product&#8217;s assigned probability (to 35% from 15%).

Abzena inside product progresses to Phase II

Abzena plc

Abzena inside product progresses to Phase II